UY37072A - Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen - Google Patents

Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Info

Publication number
UY37072A
UY37072A UY0001037072A UY37072A UY37072A UY 37072 A UY37072 A UY 37072A UY 0001037072 A UY0001037072 A UY 0001037072A UY 37072 A UY37072 A UY 37072A UY 37072 A UY37072 A UY 37072A
Authority
UY
Uruguay
Prior art keywords
phosphinans
azaphosphinans
pharmaceutical compositions
compositions containing
preparation procedure
Prior art date
Application number
UY0001037072A
Other languages
English (en)
Inventor
Schaffner Arnaud-Pierre
Alain Rupin
Philippe Gloanec
Sansilvestri-Morel Patricia
Philippe Mennecier
Vallez Marie-Odile
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55752640&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY37072(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of UY37072A publication Critical patent/UY37072A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65846Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de fórmula (I)en la que: Ak1 representa una cadena alquilo, X representa -(CH2)m-, -CH(R)-, -N(R)-, -CH2-N(R)-, –N(R)-CH2- o -CH2-N(R)-CH2-, m y R son tales como se han definido en la descripción, R1 y R2 representan cada uno H cuando X representa -(CH2)m-, -CH(R)-, -N(R)-, -CH2-N(R)- o –N(R)-CH2-, o bien forman juntos una unión cuando X representa -CH2-N(R)-CH2-, 15 R3 representa NH2, Cy-NH2, Cy-Ak3-NH2 o piperidin-4-ilo, Cy y Ak3 son tales como se han definido en la descripción, R4 y R5, idénticos o diferentes, representan cada uno H o F, sus isómeros ópticos, así como sus sales de adición a un ácido farmacéuticamente aceptable. Medicamentos.
UY0001037072A 2016-01-14 2017-01-11 Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen UY37072A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1670004A FR3046793B1 (fr) 2016-01-14 2016-01-14 Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
UY37072A true UY37072A (es) 2017-07-31

Family

ID=55752640

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037072A UY37072A (es) 2016-01-14 2017-01-11 Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Country Status (47)

Country Link
US (2) US10138260B2 (es)
EP (1) EP3271368B1 (es)
JP (1) JP2019504070A (es)
KR (1) KR20180101522A (es)
CN (1) CN108495857A (es)
AR (1) AR107433A1 (es)
AU (1) AU2017207003B2 (es)
BR (1) BR112018014020A2 (es)
CA (1) CA3011184C (es)
CL (1) CL2018001862A1 (es)
CO (1) CO2018007271A2 (es)
CU (1) CU20180072A7 (es)
CY (1) CY1121154T1 (es)
DK (1) DK3271368T3 (es)
DO (1) DOP2018000165A (es)
EA (1) EA035072B1 (es)
EC (1) ECSP18051972A (es)
ES (1) ES2709376T3 (es)
FR (1) FR3046793B1 (es)
GE (1) GEP20207092B (es)
HK (1) HK1244283B (es)
HR (1) HRP20190193T1 (es)
HU (1) HUE042924T2 (es)
IL (1) IL260425B (es)
JO (1) JO3660B1 (es)
LT (1) LT3271368T (es)
MA (1) MA41798B1 (es)
MD (1) MD3271368T2 (es)
ME (1) ME03305B (es)
MX (1) MX367319B (es)
NI (1) NI201800073A (es)
PE (1) PE20181503A1 (es)
PH (1) PH12018501373A1 (es)
PL (1) PL3271368T3 (es)
PT (1) PT3271368T (es)
RS (1) RS58338B1 (es)
RU (1) RU2729641C2 (es)
SG (1) SG11201805757WA (es)
SI (1) SI3271368T1 (es)
SV (1) SV2018005721A (es)
TN (1) TN2018000226A1 (es)
TR (1) TR201820430T4 (es)
TW (1) TWI625334B (es)
UA (1) UA121275C2 (es)
UY (1) UY37072A (es)
WO (1) WO2017121969A1 (es)
ZA (1) ZA201804391B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200300070A (et) * 2000-08-17 2005-02-15 Pfizer Inc. Asendatud imidasoolid kui TAFIa inhibiitorid
SE0103272D0 (sv) * 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
WO2003076416A1 (en) * 2002-03-08 2003-09-18 Warner-Lambert Company Llc Oxo azabicyclic compounds
US7420000B2 (en) * 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
WO2005058330A1 (en) * 2003-12-17 2005-06-30 Quatrx Pharmaceuticals Co. Phosphorus containing compounds useful for the regulation of ldl and lp(a) levels
EP1874322A1 (en) * 2005-04-18 2008-01-09 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
WO2008156726A1 (en) * 2007-06-20 2008-12-24 Merck & Co., Inc. Inhibitors of janus kinases
FR2920773B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2012002925A (es) * 2009-09-09 2012-08-03 Gilead Sciences Inc Inhibidores de virus flaviviridae.
BR112014030284B1 (pt) * 2012-07-18 2021-11-30 Sunshine Lake Pharma Co., Ltd Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
ZA201804391B (en) 2020-01-29
CA3011184A1 (fr) 2017-07-20
NI201800073A (es) 2018-09-06
DOP2018000165A (es) 2018-09-15
JO3660B1 (ar) 2020-08-27
HRP20190193T1 (hr) 2019-04-05
ME03305B (me) 2019-10-20
CN108495857A (zh) 2018-09-04
EA201891599A1 (ru) 2019-01-31
PE20181503A1 (es) 2018-09-18
AU2017207003B2 (en) 2020-10-08
ES2709376T3 (es) 2019-04-16
TWI625334B (zh) 2018-06-01
HUE042924T2 (hu) 2019-07-29
US10138260B2 (en) 2018-11-27
AU2017207003A1 (en) 2018-07-26
ECSP18051972A (es) 2018-07-31
BR112018014020A2 (pt) 2018-12-11
AR107433A1 (es) 2018-05-02
RU2729641C2 (ru) 2020-08-11
MA41798A (fr) 2018-01-24
FR3046793B1 (fr) 2018-01-05
RU2018129027A (ru) 2020-02-14
TR201820430T4 (tr) 2019-01-21
EP3271368A1 (fr) 2018-01-24
MX2018008639A (es) 2018-11-19
KR20180101522A (ko) 2018-09-12
CU20180072A7 (es) 2018-10-04
RU2018129027A3 (es) 2020-03-19
JP2019504070A (ja) 2019-02-14
TN2018000226A1 (fr) 2019-10-04
WO2017121969A1 (fr) 2017-07-20
CA3011184C (fr) 2020-09-29
PH12018501373B1 (en) 2019-02-27
HK1244283B (zh) 2019-11-22
UA121275C2 (uk) 2020-04-27
SV2018005721A (es) 2018-09-06
MA41798B1 (fr) 2018-11-30
US10654878B2 (en) 2020-05-19
PL3271368T3 (pl) 2019-04-30
EA035072B1 (ru) 2020-04-23
PT3271368T (pt) 2018-12-04
CO2018007271A2 (es) 2018-07-19
TW201726697A (zh) 2017-08-01
CL2018001862A1 (es) 2018-10-05
GEP20207092B (en) 2020-04-10
EP3271368B1 (fr) 2018-10-31
CY1121154T1 (el) 2020-05-29
LT3271368T (lt) 2018-12-10
AU2017207003A2 (en) 2018-10-04
SI3271368T1 (sl) 2019-02-28
US20190031693A1 (en) 2019-01-31
PH12018501373A1 (en) 2019-02-27
FR3046793A1 (fr) 2017-07-21
IL260425B (en) 2020-05-31
MX367319B (es) 2019-08-15
US20180016288A1 (en) 2018-01-18
DK3271368T3 (da) 2019-02-25
SG11201805757WA (en) 2018-08-30
RS58338B1 (sr) 2019-03-29
MD3271368T2 (ro) 2019-03-31

Similar Documents

Publication Publication Date Title
ECSP109944A (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met
NI201800132A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO6331467A2 (es) Nuevos derivados de imidazo(1,2-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
UY30857A1 (es) Nuevos derivados de n,n'-2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY30859A1 (es) Nuevos derivados de 2-anilino-4-heteroarilpirimidinas , su preparacion, como medicamentos, composiciones farmacéuticas y especialmente como inhibidores de ikk
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
AR082444A1 (es) Formulacion farmaceutica que comprende un inhibidor de fosfodiesterasa
NI201100218A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
AR109168A1 (es) Sales de derivados de 2,6-dimetilpirimidona y sus usos
ECSP13012838A (es) Nuevos compuestos de benzodioxol-piperazina
CO6420339A2 (es) Derivados de 6-(6-sustituido-triazolopiridacina-sulfanil) 5-fluoro-benzotiazoles y 5-fluoro-bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met
PE20210550A1 (es) Compuestos de 4-metildihidropirimidinona y su uso farmaceutico
CO2018007271A2 (es) Nuevos derivados de fosfinanos y azafosfinanos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP12012329A (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmacéuticas que la contienen
CO6400223A2 (es) Derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met
UY33927A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY33072A (es) Nuevos derivados de azabiciclo[3.1.0.]hex-2-ilo, su procedimiento de preparación y las composiciones farmacéuticas que los contienen